Literature DB >> 23285463

Can vitamin B-complex aggravate the carbamazepine induced toxic epidermal necrolysis?

Mayuresh V Fegade1, Sushama A Bhounsule, Ian Pereira.   

Abstract

Toxic Epidermal Necrolysis (TEN), which is also known as Lyell's syndrome, is a widespread, life-threatening, mucocutaneous disease that is particularly observed secondary to drugtaking and less commonly secondary to infections and immunization. Carbamazepine is associated with benign pruritic rash in 10-15% of the patients, but the life threatening dermatological syndromes like exfoliative dermatitis, erythema multiforme, the Stevens-Johnson Syndrome (SJS) and TEN are rarely seen with the carbamazepine treatment. The 32 year old female suffering from chronic backache, who was prescribed carbamazepine along with an intravenous combination of vitamin B-complex and calcium, developed fever, cough and mucocutaneous manifestations of TEN after 15 days of the treatment. She was treated in the hospital with systemic steroids, intravenous immunoglobulins, antibiotics, intravenous fluids and supportive care. In spite of the above treatment, the patient could not survive for more than seven days.

Entities:  

Keywords:  Carbamazepine; Drug reaction; Systemic steroids; Toxic epidermal necrolysis

Year:  2012        PMID: 23285463      PMCID: PMC3527803          DOI: 10.7860/JCDR/2012/4744.2566

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  13 in total

Review 1.  Toxic epidermal necrolysis (Lyell syndrome).

Authors:  J C Roujeau; O Chosidow; P Saiag; J C Guillaume
Journal:  J Am Acad Dermatol       Date:  1990-12       Impact factor: 11.527

Review 2.  Severe adverse cutaneous reactions to drugs.

Authors:  J C Roujeau; R S Stern
Journal:  N Engl J Med       Date:  1994-11-10       Impact factor: 91.245

Review 3.  Life-threatening acute adverse cutaneous drug reactions.

Authors:  Ronni Wolf; Edith Orion; Batsheva Marcos; Hagit Matz
Journal:  Clin Dermatol       Date:  2005 Mar-Apr       Impact factor: 3.541

Review 4.  Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding.

Authors:  Lars E French
Journal:  Allergol Int       Date:  2006-03       Impact factor: 5.836

5.  Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.

Authors:  Shuen-Iu Hung; Wen-Hung Chung; Shiou-Hwa Jee; Wen-Chieh Chen; Yun-Ting Chang; Woan-Ruoh Lee; Shu-Ling Hu; Meng-Tse Wu; Gwo-Shing Chen; Tak-Wah Wong; Pa-Fan Hsiao; Wei-Hsuan Chen; Han-Yu Shih; Wu-Hsiang Fang; Chun-Yu Wei; Yi-Hui Lou; Yau-Li Huang; Juei-Jueng Lin; Yuan-Tsong Chen
Journal:  Pharmacogenet Genomics       Date:  2006-04       Impact factor: 2.089

6.  Stevens-Johnson syndrome in an HIV-infected patient.

Authors:  M Blitz; E Spivack; S M Kerpel; P D Freedman
Journal:  AIDS Read       Date:  1999 May-Jun

7.  The outcome of Stevens-Johnson syndrome treated with corticosteroids.

Authors:  S Cheriyan; R Patterson; P A Greenberger; L C Grammer; J Latall
Journal:  Allergy Proc       Date:  1995 Jul-Aug

8.  Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme.

Authors:  S Bastuji-Garin; B Rzany; R S Stern; N H Shear; L Naldi; J C Roujeau
Journal:  Arch Dermatol       Date:  1993-01

9.  Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians.

Authors:  Timir Y Mehta; Laxman M Prajapati; Bharti Mittal; Chaitanya G Joshi; Jayesh J Sheth; Dinesh B Patel; Dinkar M Dave; Ramesh K Goyal
Journal:  Indian J Dermatol Venereol Leprol       Date:  2009 Nov-Dec       Impact factor: 2.545

10.  Clinical spectrum of drug rashes due to antiepileptics.

Authors:  V K Sharma; M Vatve; I M Sawhney; B Kumar
Journal:  J Assoc Physicians India       Date:  1998-07
View more
  1 in total

1.  Stevens-Johnson syndrome/toxic epidermal necrolysis presumably induced by norfloxacin.

Authors:  Jolanta Maciejewska; Marek Jankowski; Barbara Zegarska; Rafał Czajkowski
Journal:  Postepy Dermatol Alergol       Date:  2014-06-13       Impact factor: 1.837

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.